Anti-interleukin-18 therapy in murine models of inflammatory bowel disease

Pathobiology

Volumn 70, Issue 3, 2003, Pages 164-169

  Lochner, Matthias ^a   Förster, Irmgard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Inst Med Mikrobiol Immunol/Hyg   (Germany)

Author keywords

Anti interleukin 18 therapy; Crohn's disease; Inflammatory bowel disease; Interleukin 18

Indexed keywords

ADENOVIRUS VECTOR; BINDING PROTEIN; COMPLEMENTARY RNA; CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SK113AE 4; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BACTERIAL INFECTION; CELL ACTIVATION; CHRONIC DISEASE; COLITIS; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENTERITIS; EXPERIMENTAL MOUSE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PARASITOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; TISSUE LEVEL; UPREGULATION; VIRAL GENE THERAPY;

ANIMALS; ANTIBODIES, BLOCKING; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-18; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; RNA, ANTISENSE;

MURINAE;

EID: 0037262797     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068149     Document Type: Conference Paper

References (53)

1. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T: Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989;57:590-595.
2. Okamura H, Tsutsi H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
3. Fantuzzi G, Dinarello CA: Interleukin-18 and interleukin-1 beta: Two cytokine substrates for ICE (caspase-1). J Clin Immunol 1999;19:1-11.
4. Stoll S, Jonuleit H, Schmitt E, et al: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998;28:3231-3239.
5. Nakanishi K, Yoshimoto T, Tsutsui H, Oka-mura H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001;12:53-72.
6. Takeuchi M, Nishizaki Y, Sano O, Ohta T, Ikeda M, Kurimoto M: Immunohistochemical and immuno-electron-microscopic detection of interferon-gamma-inducing factor ('interleukin-18') in mouse intestinal epithelial cells. Cell Tissue Res 1997;289:499-503.
7. Cameron LA, Taha RA, Tsicopoulos A, et al: Airway epithelium expresses interleukin-18. Eur Respir J 1999;14:553-559.
8. Yoshimoto T, Takeda K, Tanaka T, et al: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998;161:3400-3407.
9. Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach E: The costimulatory effect of IL-18 on the induction of antigen-specific IFN-gamma production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor beta2 subunit. Eur J Immunol 2000;4:1113-1119.
10. Munder M, Mallo M, Eichmann K, Modolell M: Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med 1998;187:2103-2108.
11. Fukao T, Matsuda S, Koyasu S: Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells. J Immunol 2000;164:64-71.
12. Munder M, Mallo M, Eichmann K, Modolell M: Direct stimulation of macrophages by IL-12 and IL-18 - A bridge built on solid ground. Immunol Lett 2001;75:159-160.
13. Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW: Interleukin-18 induces production of proinflammatory cytokines in mice: No intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur J Immunol 2000;30:3057-3060.
14. Horwood NJ, Udagawa N, Elliott J, et al: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998;101:595-603.
15. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA: Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711-721.
16. Olee T, Hashimoto S, Quach J, Lotz M: IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999;162:1096-1100.
17. Xu D, Trajkovic V, Hunter D, et al: IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000;30:3147-3156.
18. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
19. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE: IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 1996;271:3967-3970.
20. Born TL, Thomassen E, Bird TA, Sims JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998;273:29445-29450.
21. Debets R, Timans JC, Churakowa T, et al: IL-18 receptors, their role in ligand binding and function: Anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol 2000;165:4950-4956.
22. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M: Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999;10:127-136.
23. Kim SH, Eisenstein M, Reznikov L, et al: Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 2000;97:1190-1195.
24. Xiang Y, Moss B: IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA 1999;96:11537-11542.
25. Takeda K, Tsutsui H, Yoshimoto T, et al: Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-390.
26. Wei XQ, Leung BP, Niedbala W, et al: Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureusinfection in IL-18-deficient mice. J Immunol 1999;163:2821-2888.
27. Hochholzer P, Lipford GB, Wagner H, Pfeffer K, Heeg K: Role of interleukin-18 (IL-18) during lethal shock: Decreased lipopolysaccharide sensitivity but normal superantigen reaction in IL-18-deficient mice. Infect Immun 2000;68:3502-3508.
28. Swain SL: Interleukin 18:tipping the balance towards a T helper cell 1 response. J Exp Med 2001;194:F11-F14.
29. Cai G, Kastelein R, Hunter CA: Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000;68:6932-6938.
30. Sakao Y, Takeda K, Tsutsui H, et al: IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol 1999;11:471-480.
31. Wild JS, Sigounas A, Sur N, et al: IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol 2000;164:2701-2710.
32. Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG: IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol 2000;165:3099-3104.
33. Gracie JA, Forsey RJ, Chan WL, et al: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-1401.
34. Joosten LA, van De Loo FA, Lubberts E, et al: An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol Methods 2000;165:6553-6558.
35. Plater-Zyberk C, Joosten LA, Helsen MM, et al: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001;108:1825-1832.
36. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U: Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med 2002;195:245-257.
37. Powrie F, Leach MW, Mauze S, Menon S, Cad-dle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-562.
38. Targan SR, Murphy LK: Clarifying the causes of Crohn's. Nat Med 1995;1:1241-1243.
39. Parronchi P, Romagnani P, Annunziato F, et al: Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-832.
40. Monteleone G, Trapasso F, Parrello T, et al: Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999;163:143-147.
41. Pizarro TT, Michie MH, Bentz M, et al: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells. J Immunol 1999;162:6829-6835.
42. Kanai T, Watanabe M, Okazawa A, et al: Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 2000;119:1514-1553.
43. Chikano S, Sawada K, Shimoyama T, et al: IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 2000;47:779-786.
44. Ten Hove T, Corbaz A, Amitai H, et al: Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001;121:1372-1379.
45. Kanai T, Watanabe M, Okazawa A, et al: Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001;121:875-888.
46. Siegmund B, Fantuzzi G, Rieder F, et al: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-R1273.
47. Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF: Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002;168:411-420.
48. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA: IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001;98:13249-13254.
49. Camoglio L, te Velde AA, de Boer A, ten Kate FJ, Kopf M, van Deventer SJ: Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol 2000;30:1486-1495.
50. Lochner M, Wagner H, Classen M, Forster I: Generation of neutralizing mouse anti-mouse IL-18 antibodies for inhibition of inflammatory responses in vivo. J Immunol Methods 2002;259:149-157.
51. Lipford GB, Heeg K, Wagner H: Bacterial DNA as immune cell activator. Trends Microbiol 1998;6:496-500.
52. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-1471.
53. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.